Editorials

193  Inflammatory Cell Markers as Indicators of Atherosclerotic Renovascular Disease
    Stephen C. Textor and Lilach O. Lerman
    See related article on page 224.

196  Racial and Ethnic Disparities in End Stage Renal Disease: Access Failure
    Yoshio N. Hall
    See related article on page 289.

Original Articles

Acute Kidney Injury /Acute Renal Failure

199  Association of AKI with Adverse Outcomes in Burned Military Casualties
    Ian J. Stewart, Molly A. Tilley, Casey L. Cotant, James K. Aden, Christopher Gisler, Hana K. Kwan, Jeffery McCorcle,
    Evan M. Renz, and Kevin K. Chung

Chronic Kidney Disease

207  Prolactin Levels, Endothelial Dysfunction, and the Risk of Cardiovascular Events and Mortality in Patients
    with CKD
    Juan Jesús Carrero, John Kyriazis, Alper Sonmez, Ioannis Tzanakis, Abdul Rashid Qureshi, Peter Stenvinkel,
    Mutlu Saglam, Kostas Stylianou, Halil Yaman, Abdullah Taslipsin, Abdulgaffar Vural, Mahmut Gok,
    Mujdat Yenicesu, Eugene Daphnis, and Mahmut Ilker Yılmaz

216  Ergocalciferol Supplementation in Children with CKD Delays the Onset of Secondary Hyperparathyroidism:
    A Randomized Trial
    Rukshana Shroff, Mandy Wan, Ambrose Gultett, Sarah Ledermann, Rachel Shute, Craig Knott, David Wells,
    Helen Aitkenhead, Bahee Manickavasagar, William van’t Hoff, and Lesley Rees

Clinical Immunology and Pathology

224  Local and Systemic Cellular Immunity in Early Renal Artery Atherosclerosis
    Carol Kotliar, Luis Juncos, Felipe Inserra, Elena M.V. de Cavanagh, Eduardo Chuluyan, Jorge B. Aquino, Alejandro Hita,
    Carlos Navari, and Ramiro Sánchez
    See related editorial on page 193.

Clinical Nephrology

231  Renal Monoclonal Immunoglobulin Deposition Disease: A Report of 64 Patients from a Single Institution
    Samih H. Nasr, Anthony M. Valeri, Lynn D. Cornell, Mary E. Fidler, Sanjeev Sethi, Vivette D. D'Agati, and
    Nelson Leung

240  Glucocorticoids and Relapse and Infection Rates in Anti-Neutrophil Cytoplasmic Antibody Disease
    JulieAnne G. McGregor, Susan L. Hogan, Yichun Hu, Caroline E. Jennette, Ronald J. Falk, and
    Patrick H. Nachman

248  Soluble Klotho and Autosomal Dominant Polycystic Kidney Disease
    Ivana Pavik, Philippe Jaeger, Lena Ebner, Diane Poster, Fabienne Krauer, Andreas D. Kistler, Katharina Rentsch,
    Gustav Andrisek, Carsten A. Wagner, Olivier Devuyst, Rudolf P. Wüthrich, Christoph Schmid, and
    Andreas L. Serra
258 Reversibility of the Effects of Aliskiren in the Renal Versus Systemic Circulation
Markus P. Schneider, Rolf Janka, Thomas Ziegler, Ulrike Raff, Martin Ritt, Christian Ott, Roland Veelken, Michael Uder, and Roland E. Schmieder

265 Causes of Alternative Pathway Dysregulation in Dense Deposit Disease

Epidemiology and Outcomes
275 The Risk for Medial Arterial Calcification in CKD
Nada Abou Hassan, Ellen T. D’Orsi, Carl J. D’Orsi, and W. Charles O’Neill

280 Obesity and Mortality Risk among Younger Dialysis Patients
Ellen K. Hoogeveen, Nynke Halbesma, Kenneth J. Rothman, Theo Stijnen, Sandra van Dijk, Friedo W. Dekker, Elisabeth W. Boeschoten, and Renée de Mutsert, for the Netherlands Cooperative Study on the Adequacy of Dialysis-2 (NECOSAD) Study Group

289 Hispanic Ethnicity and Vascular Access Use in Patients Initiating Hemodialysis in the United States
Cristina M. Arce, Aya A. Mitani, Benjamin A. Goldstein, and Wolfgang C. Winkelmayer
See related editorial on page 196.

ESRD and Chronic Dialysis
297 A Randomized Controlled Trial Comparing Mupirocin and Polysporin Triple Ointments in Peritoneal Dialysis Patients: The MP³ Study
Rory F. McQuillan, Ernest Chiu, Sharon Nessim, Charmaine E. Lok, Janet M. Roscoe, Paul Tam, and Sarbjeet Vanita Jassal

304 Relationship between CRP Polymorphism and Cardiovascular Events in Chinese Peritoneal Dialysis Patients
Peter Yam-Kau Poon, Cheuk-Chun Szeto, Bonnie Ching-Ha Kwan, Kai-Ming Chow, and Philip Kam-Tao Li

Solar-Assisted Hemodialysis
John W. M. Agar, Anthony Perkins, and Alwie Tjipto

Hypertension
315 Association of Urinary Sodium/Potassium Ratio with Blood Pressure: Sex and Racial Differences
S. Susan Hedayati, Abu T. Minhaajuddin, Adeel Ijaz, Orson W. Moe, Essam F. Elsayed, Robert F. Reilly, and Chou-Long Huang

Mineral Metabolism/Bone Disease
323 Renal Phosphate Loss in Long-Term Kidney Transplantation
Supinda Sirilak, Kamonwan Chatsrisak, Atiporn Ingsathit, Surasak Kantachuvessiri, Vasant Sumethkul, Wasana Stitchantrakul, Piyanuch Radinahamed, and Sinee Disthabanchong

Renal Transplantation
332 Dialysis Modality and Outcomes in Kidney Transplant Recipients
Miklos Z. Molnar, Rajnish Mehrotra, Uyen Duong, Suphamai Bunnapradist, Lilia R. Lukowsky, Mahesh Krishnan, Csaba P. Kovacsdy, and Kamyar Kalantar-Zadeh

Attending Rounds
342 Attending Rounds: Microangiopathic Hemolytic Anemia with Renal Insufficiency
William F. Clark and Ainslie Hildebrand

Commentary
348 The New FDA Labeling for ESA—Implications for Patients and Providers
Braden J. Manns and Marcello Tonelli

354 Erythropoietic Stimulating Agents and Quality of a Patient’s Life: Individualizing Anemia Treatment
Alan S. Kliger, Steven Fishbane, and Fredric O. Finkelstein
Mini-Review

358 Vitamin D Therapy in Chronic Kidney Disease and End Stage Renal Disease
Michal L. Melamed and Ravi I. Thadhani

In-Depth Review

366 The Living Kidney Donor Evaluation: Focus on Renal Issues
Ajay Kher and Didier A. Mandelbrot

On the Cover

What’s the diagnosis? Over the past decade, intravital multiphoton excitation fluorescence microscopy has provided stunning images and movies of the structure and function of the intact kidney with unparalleled spatial and temporal resolution. Because of its ability to directly visualize dynamic intrarenal processes in vivo without causing tissue damage, this noninvasive optical sectioning technique and imaging approach has revolutionized kidney research. This multiphoton image shows a glomerulus (lower right) in the living rat kidney that has been treated with puromycin aminonucleoside (PAN), a model of focal segmental glomerulosclerosis (FSGS). The red is albumin conjugated to Alexa594 to label the blood (plasma); green-yellow is Lucifer yellow, a freely filtered fluid marker labeling the glomerular filtrate. The nuclear dye Hoechst33342 was added to label cell nuclei (green). In this early phase of FSGS, small cysts in podocytes (unlabeled dark cells outside the glomerular capillary loops), and increased permeability of the glomerular filtration barrier (red-labeled albumin uptake in the early proximal tubule), are visible. Also, Lucifer yellow intensity in the tubular fluid nicely demonstrates the renal concentrating mechanism (intense fluorescence in the adjacent collecting duct versus the Bowman’s space and proximal tubule at the right). A corresponding video shows the filtration of Lucifer yellow injected into the carotid artery and the appearance of unlabeled podocytes (negative image). (Image and video, available online at www.cjasn.org, provided by Janos Peti-Peterdi and James Burford)